Vividion Therapeutics is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/24/2021 | Series C | $135MM | $xx.xx | $600.09MM | Acuta Capital, Arch Venture Partners, Avoro Capital Advisors, Blackrock, Boxer Capital, Bvf Partners, Casdin Capital, Driehaus Capital Management, Logos Capital, Mubadala Capital, Nextech Invest, Ra Capital Management, Softbank, Surveyor Capital, T. Rowe Price Associates, Versant Ventures, Woodline Partners | |
Price per Share
$xx.xx
Shares Outstanding
64,285,721
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Acuta Capital, Arch Venture Partners, Avoro Capital Advisors, Blackrock, Boxer Capital, Bvf Partners, Casdin Capital, Driehaus Capital Management, Logos Capital, Mubadala Capital, Nextech Invest, Ra Capital Management, Softbank, Surveyor Capital, T. Rowe Price Associates, Versant Ventures, Woodline Partners
|
||||||
04/30/2019 | Series B | $82MM | $xx.xx | $304.43MM | Alexandria Venture Investments, Altitude Life Science Ventures, Arch, Bvf Partners, Cardinal, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Ventures, Trinitas Capital, Versant | |
Price per Share
$xx.xx
Shares Outstanding
57,543,868
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Altitude Life Science Ventures, Arch, Bvf Partners, Cardinal, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Ventures, Trinitas Capital, Versant
|
||||||
02/02/2017 | Series A-3 | $5.9MM | $xx.xx | $118.29MM | Arch Venture Partners, Cardinal Partners, Versant Venture | |
Price per Share
$xx.xx
Shares Outstanding
6,550,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Cardinal Partners, Versant Venture
|
||||||
02/02/2017 | Series A-2 | $40.4MM | $xx.xx | $118.29MM | Arch Venture Partners, Cardinal Partners, Versant Venture | |
Price per Share
$xx.xx
Shares Outstanding
67,333,334
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Cardinal Partners, Versant Venture
|
||||||
03/31/2016 | Series A | $4.53MM | $xx.xx | $11.32MM | Cardinal Partners | |
Price per Share
$xx.xx
Shares Outstanding
18,118,465
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cardinal Partners
|